Welcome to our dedicated page for Orthopedia SEC filings (Ticker: KIDS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Medical device filings can be dense; OrthoPediatrics’ reports add an extra layer of complexity with clinical trial data, FDA submissions, and unique pediatric implant metrics spread across hundreds of pages. Investors often ask, “Where is the limb deformity revenue?” or “Did executives buy shares ahead of a 510(k) clearance?” Stock Titan answers by delivering OrthoPediatrics SEC filings explained simply through concise AI-powered summaries as soon as each document lands on EDGAR.
Need the numbers fast? Our platform links every OrthoPediatrics quarterly earnings report 10-Q filing to instant trend charts, while the latest OrthoPediatrics annual report 10-K simplified highlights segment sales, R&D spending, and regulatory milestones. Receive alerts on OrthoPediatrics insider trading Form 4 transactions and drill further with OrthoPediatrics Form 4 insider transactions real-time to spot buying or selling by surgeons turned directors. Material announcements are decoded in seconds with OrthoPediatrics 8-K material events explained, and each OrthoPediatrics proxy statement executive compensation call-out lets you see how leadership pay aligns with growth.
Behind the scenes, our AI dissects language, numbers, and footnotes, turning dense paragraphs into clear takeaways, so understanding OrthoPediatrics SEC documents with AI becomes part of your daily workflow. Practical uses abound:
- Compare revenue trends using our OrthoPediatrics earnings report filing analysis
- Flag sudden share movements via OrthoPediatrics executive stock transactions Form 4
- Track device approvals and recalls without sifting through PDFs
With comprehensive coverage, real-time updates, and expert commentary, Stock Titan turns complicated disclosures into actionable insights—so you can focus on evaluating growth in pediatric orthopedics, not downloading filings.
OrthoPediatrics Corp. (KIDS) Form 4: Chief Operating Officer and Chief Financial Officer Fred Hite purchased 5,076 shares of OrthoPediatrics common stock in the open market on 08/21/2025 at $19.41 per share, bringing his beneficial ownership to 213,065 shares including 150,360 restricted shares. The filing notes the purchase was matchable under Section 16(b) with a prior sale, and Mr. Hite disgorged $27,664.20 to the company representing the full short-swing profit.
The transaction was reported by an attorney-in-fact on 08/25/2025. The Form 4 shows direct ownership and does not report derivative transactions. No additional executive departures, changes in compensation, or forward-looking statements are included in the filing.
OrthoPediatrics announced the Board accepted the resignation of director Terry Schlotterback due to retirement, effective August 8, 2025; the filing states the departure was not due to any disagreement with the Company. The Board appointed Kelly Fischer to fill the vacancy and to serve in the director class expiring at the annual stockholder meeting in 2026. Ms. Fischer has been Senior Vice President and Chief Financial Officer of Cook Medical since 2003 and will join the Board's Audit Committee and Compensation Committee.
For her service, Ms. Fischer will be eligible to receive a pro rata portion of the 2025 Award under the Company's Non-Employee Director Compensation Policy (described in Exhibit 10.1 to a recent Quarterly Report). The Board also agreed that the remaining 10,900 unvested restricted shares previously granted to Mr. Schlotterback will remain outstanding and continue to vest on their scheduled timelines as though he remained a director. The company disclosed no material plans, contracts or related-party transactions involving Ms. Fischer.
FAQ
What is the current stock price of Orthopedia (KIDS)?
What is the market cap of Orthopedia (KIDS)?
